menu
    • menu
    [{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oruka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Bucindolol Hydrochloride

    Menu

    Bucindolol Hydrochloride

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Oruka Therapeutics

    U.S.A arrow
    ISPE Aseptic Conference
    Not Confirmed

    Oruka Therapeutics

    U.S.A arrow
    ISPE Aseptic Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bucindolol Hydrochloride

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

    Details : In a GENETIC-AF Phase 2b clinical trial, the prevalence of bradycardia was significantly lower for Gencaro compared to metoprolol. Gencaro, is an investigational, pharmacologically unique beta-blocker for the treatment of atrial fibrillation in heart fai...

    Product Name : Gencaro

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 04, 2022

    Lead Product(s) : Bucindolol Hydrochloride

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Oruka Therapeutics

    U.S.A arrow
    ISPE Aseptic Conference
    Not Confirmed

    Oruka Therapeutics

    U.S.A arrow
    ISPE Aseptic Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bucindolol Hydrochloride

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Clinical Data of Gencaro for Atrial Fibrillation in Heart Failure Featured in Three Presentations at 2020 Hear...

    Details : New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 07, 2020

    Lead Product(s) : Bucindolol Hydrochloride

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth